News

February 5, 2019February 6, 2019

ICD-10 Codes, ‘Really Important’ to Rare Disease Patients, Soon Up for Fresh Consideration

News

G71.01 is, literally, the code for Duchenne muscular dystrophy. Q93.51 stands for Angelman syndrome, and G40.419 covers generalized and treatment-resistant epilepsies, which groups like Orphanet and the American Epilepsy Society ... Read more

February 4, 2019

Belimumab Maintenance Fails to Delay Relapse in AAV Patients, Phase 3 Trial Suggests

News

A combination of belimumab plus standard maintenance treatment is no better than standard of care alone at delaying relapse in ANCA-associated vasculitis (AAV) patients in remission, a Phase 3 clinical trial shows. ... Read more

January 31, 2019

New Plans Announced for Full Marketing Approval of Avacopan as Treatment for ANCA Vasculitis

News

In light of upcoming Phase 3 data, ChemoCentryx and Vifor Fresenius Medical Care Renal Pharma have decided not to pursue the conditional approval of avacopan in Europe for patients with ANCA-associated ... Read more

January 29, 2019

ANCA Testing Useful but Not Sufficient for AAV Diagnosis in Patients with Neurological Symptoms, Study Says

News

Anti-neutrophil cytoplasmic autoantibody (ANCA) testing is useful for the early diagnosis of ANCA-associated vasculitis (AAV) in patients with central nervous system symptoms, allowing for timely treatment and a better prognosis, ... Read more

January 28, 2019

Gene Expression Analysis of AAV Tissue Sheds New Light on Disease Progression, Study Finds

News

An analysis of the gene expression and gene pathways in different tissues affected by ANCA vasculitis has provided new information about the mechanisms involved in disease progression, a study ... Read more

January 24, 2019

Study Finds Predictors of Renal Outcomes in Children with ANCA Vasculitis

News

Impaired renal function, the presence of ANCA antibodies against the MPO protein, and a score of 2 or higher in the five-factor score — which measures prognosis at diagnosis ... Read more

January 22, 2019

Mycophenolate Mofetil Can Replace Cyclophosphamide at Inducing Remission in Some AAV Patients, Clinical Trial Suggests

News

The immunosuppressant agent mycophenolate mofetil (MMF) is similar to standard cyclophosphamide at inducing remission in ANCA-associated vasculitis (AAV) patients, but it seems to be associated with a higher relapse ... Read more

January 21, 2019

Markers of Renal Outcomes in Subclass of ANCA Vasculitis Patients Found, Study Says

News

Glomerular filtration rate (GFR), a kidney function marker, and the presence of atrophy in the kidney’s tubules predict renal survival in ANCA vasculitis patients with the sclerotic class of glomerulonephritis ... Read more

January 17, 2019

Patient Develops AAV Due to Familial Mediterranean Fever, Case Study Shows

News

Blood vessel inflammation caused by ANCA antibodies should be considered in the differential diagnosis of familial Mediterranean fever with hyperthyroidism, a case study shows. The study, “Antineutrophil cytoplasmic antibody-positive ... Read more

January 15, 2019

Case Report Shows for First Time That AAV May Also Affect Brain, Spinal Cord

News

Researchers reported for the first time the case of a patient with ANCA-associated vasculitis whose condition caused bleeding in the brain and spinal cord, most likely because of a ... Read more

Pin It on Pinterest